<DOC>
	<DOCNO>NCT00796159</DOCNO>
	<brief_summary>This Post-Marketing Surveillance study evaluate Efficacy , Tolerability Safety Olmesartan medoxomil 20 mg combination 12.5 MG hydrochlorothiazide subject mild moderate essential hypertension</brief_summary>
	<brief_title>Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide</brief_title>
	<detailed_description>Non Probability Sampling</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Male Female patient 18 65 y/old Patient previously take lowdose medoxomil ARB alone uncontrolled BP Patient uncontrolled mild moderate hypertension ( SBP &gt; = 140 &lt; =179 mmHg OR DBP &gt; =90 &lt; =109 mmHg ) Pregnant Lactating woman History secondary hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Efficacy ; Tolerability ; Safety ; Essential Hypertension</keyword>
</DOC>